Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5071-5080 Newer>

Chemistry World September 1, 2008 James Mitchell Crow	Drug discovery on a chip Scientists in the US have, for the first time, used microfluidics to discover drug leads. The team's lab-on-a-chip device revealed inhibitors of a key membrane-bound protein in hepatitis C virus
Chemistry World September 2008 Paul Docherty	Column: Totally Synthetic The need to discover new antibiotics to treat resistant strains of bacteria is a well- documented and discussed challenge for chemists.
Chemistry World August 29, 2008 John Bonner	Chip test for IVF embryos US researchers may have found a new way to assess the health of embryos produced by in vitro fertilization, using a lab on a chip approach to measure their uptake of nutrients.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool August 28, 2008 Brian Orelli	Stryker Strikes Back The orthopedics maker sues to stop a costly federal investigation.
The Motley Fool August 28, 2008 Brian Lawler	Cell Genesys Takes a Body Blow Can it make a comeback after a failed cancer study of its lead drug?
<Older 5071-5080 Newer> Return to current articles.